Lymphomas
City of Hope is one of the largest and most successful treatment centers in the country for patients with lymphoma. Because of our vast experience in treating patients with this type of cancer, our specialists lead the field of hematopoietic cell transplantation (HCT) with excellent outcomes. Since 1976, City of Hope has performed more than 11,000 transplants for patients from virtually every state and around the world. 
 
As one of a select number of institutes to attain the elite designation of Comprehensive Cancer Center by the National Cancer Institute, City of Hope is acknowledged as a leader in cancer research and treatment.  We collaborate with scientists at City of Hope and other nationally recognized research institutions to develop tomorrow’s breakthrough treatments today. With our extensive program of clinical trials, newly diagnosed or relapsed lymphoma patients can find a clinical trial targeted to their condition. 
 

A Commitment to Create

At City of Hope, we also create new treatments for lymphoma. We pioneered “mini” hematopoietic cell transplants that allow for transplantation in older lymphoma patients.  We offer the broadest range of therapeutic options available, including protocols developed here at City of Hope and funded in part by the National Institutes of Health. Through ongoing clinical trials, our physicians and researchers continue to lead the way in improving outcomes in lymphoma patients.   
 
City of Hope has pioneered innovative transplant regimens that have improved the cure rate for patients with Hodgkin lymphoma, non-Hodgkin lymphoma and other hematologic disorders. 
 
City of Hope combines both transplant and non-transplant therapies in the treatment of lymphomas. Delivered by a multidisciplinary treatment team that works closely and collaboratively, treatment planning begins upon the very first visit. Because of the close coordination among our specialists, there is a smoother transition and expedited treatment for those patients who ultimately need a stem cell transplant. In addition, lymphoma patients are at risk of developing myelodysplasia. Our researchers have developed biomarkers to determine who may be at risk of developing this complex disease. For more information about treatment approaches including chemotherapy, immunotherapy, radioimmunotherapy, adoptive T cell therapy, stem cell transplantation, click here.
 
City of Hope’s Lymphoma Specialized Program of Research Excellence (SPORE) is focused on developing translational studies to improve the detection and therapy of Hodgkin and non-Hodgkin lymphoma. The studies are aimed at creating lymphoma therapies that will reduce toxicities associated with current treatment regimens. Those new therapies can then be translated for use in older patient populations.
 
To learn more about our lymphoma program, diagnosis and treatment of lymphomas, click here.
 
 
A Leader in Lymphoma Research 

City of Hope has long been a leader in lymphoma research. Our research projects have been funded by the National Cancer Institute and many other research-based organizations. We collaborate with other leading research institutions to develop tomorrow’s breakthroughs today. With our extensive program of clinical trials, City of Hope can provide our patients access to novel therapies, including many that are not available elsewhere.
 
Our Developmental Therapeutics Program has an active portfolio of trials for patients with recurrent lymphoma, including trials of new chemotherapy and immunotherapy drugs. We are also actively involved in survivorship research.

City of Hope’s Lymphoma Specialized Program of Research Excellence (SPORE) program is focused on developing translational studies to improve the detection and therapy of Hodgkin and non-Hodgkin lymphoma. It aims to develop novel approaches derived from molecular and immunologic studies of T cell and antibody-based therapies. Its goal is also to create lymphoma therapies that will reduce toxicities associated with current treatment regimens. Those new therapies can then be translated for use in older patient populations.

To learn more about our clinical trials program and to find trials for lymphoma, click here.